Alison F. Lawton's most recent trade in Dianthus Therapeutics Inc was a trade of 12,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics Inc | Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| X4 Pharmaceuticals Inc | Alison F. Lawton | Director | 10 Jun 2024 | 45,000 | 96,667 (0%) | 0% | 0 | Common Stock | ||
| Dianthus Therapeutics Inc | Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Aeglea BioTherapeutics Inc | Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 1,950,000 | 1,950,000 | - | - | Stock Option (right to buy) | |
| Aeglea BioTherapeutics Inc | Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 43,000 | 43,000 | - | - | Director Stock Option (right to buy) | |
| X4 Pharmaceuticals Inc | Alison F. Lawton | Director | 06 Jun 2022 | 6,667 | 6,667 (0%) | 0% | 0 | Common Stock | ||
| Aeglea BioTherapeutics Inc | Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 40,000 | 40,000 | - | - | Director Stock Option (right to buy) | |
| X4 Pharmaceuticals Inc | Alison F. Lawton | Director | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | ||
| X4 Pharmaceuticals Inc | Alison F. Lawton | Director | 05 Oct 2020 | 6,854 | 6,854 | - | - | Stock Option (right to buy) |